Edition:
India

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

78.80GBp
17 Aug 2018
Change (% chg)

-0.20 (-0.25%)
Prev Close
79.00
Open
80.00
Day's High
80.00
Day's Low
78.40
Volume
518,140
Avg. Vol
3,428,698
52-wk High
127.22
52-wk Low
68.00

Latest Key Developments (Source: Significant Developments)

Vectura Appoints Paul Fry As CFO
Monday, 16 Jul 2018 

July 16 (Reuters) - Vectura Group PLC ::VECTURA APPOINTS PAUL FRY AS CFO.PAUL SUCCEEDS ANDREW DERODRA WHO, AS PREVIOUSLY ANNOUNCED, LEAVES GROUP AND BOARD ON 31 JULY 2018.  Full Article

Sosei Says Does Not Intend To Make An Offer For Vectura
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Sosei Group Corp::STATEMENT RE PRESS COMMENT.CONFIRMS THAT IT DOES NOT INTEND TO MAKE AN OFFER FOR VECTURA.SOSEI WILL, EXCEPT WITH CONSENT OF UK PANEL ON TAKEOVERS AND MERGERS, BE BOUND BY RESTRICTIONS CONTAINED IN RULE 2.8 OF CODE.  Full Article

Vectura Says CFO Decided To Leave Group
Friday, 20 Apr 2018 

April 20 (Reuters) - Vectura Group PLC ::CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR ANDREW DERODRA HAS DECIDED TO LEAVE GROUP.A SEARCH FOR HIS REPLACEMENT IS UNDERWAY AND GROUP WILL PROVIDE AN UPDATE ON HIS SUCCESSOR IN DUE COURSE.ANDREW WILL REMAIN IN HIS POSITION AT VECTURA AND ON BOARD UNTIL END OF JULY IN ORDER TO ENSURE A SMOOTH TRANSITION PROCESS.  Full Article

Vectura Group Anticipates FY 2017 Revenue In Line With Board's Expectations
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Vectura Group Plc ::FULL YEAR 2017 REVENUE ANTICIPATED TO BE IN LINE WITH BOARD'S EXPECTATIONS.FLUTIFORM PRODUCT SUPPLY REVENUE IN H2 2017 IS IN LINE WITH GUIDANCE PROVIDED.FLUTIFORMQ3 1 IN-MARKET NET SALES WERE EUR 47.8 MILLION 2 , UP 12% AT CONSTANT EXCHANGE RATES.ULTIBRO Q3 1 NET SALES OF $101 MILLION, WITH 18% GROWTH IN EUROPE YEAR-ON-YEAR.ROYALTIES FROM GSK ELLIPTA® PRODUCTS ACHIEVED £9 MILLION ANNUAL CAP IN Q3.WERE CURRENT EXCHANGE RATES TO CONTINUE THROUGH 2018, STERLING REPORTED REVENUES WOULD BE REDUCED BY APPROXIMATELY £5.0 MILLION.RESEARCH AND DEVELOPMENT COSTS IN 2018 ARE EXPECTED TO REDUCE TO £55 MILLION - £65 MILLION (PREVIOUS 2018 GUIDANCE: £65 MILLION - £75 MILLION).  Full Article

Vectura says asthma drug misses primary endpoint in Phase III trial
Tuesday, 30 Aug 2016 

Vectura Group Plc : Update on Mundipharma's European Phase III trial of flutiform ® in COPD and latest flutiform ® in-market sales . Informed by its partner mundipharma that its phase iii trial of flutiform ® did not meet primary endpoint . Mundipharma is currently undertaking an analysis of trial's other endpoints .Mundipharma has indicated that primary endpoint result will not allow it to make a regulatory filing for COPD indication in Europe.  Full Article

Vectura says asthma drug misses primary endpoint in Phase III trial
Tuesday, 30 Aug 2016 

Vectura Group Plc : Has been informed by its partner Mundipharma that its phase III trial of flutiform® did not meet primary endpoint .Mundipharma is currently undertaking an analysis of trial's other endpoints but has indicated that primary endpoint result will not allow it to make a regulatory filing for copd indication in europe..  Full Article